Skin Infection News and Research

RSS

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Heat therapy using Thermomed device effective for treatment of leishmaniasis

A single session of heat therapy using the Thermomed™ device appears to be as effective as a 10-day intravenous course of sodium stibogluconate (Pentostam) for the treatment of Leishmania major skin lesions, according to a new study by Naomi Aronson and her colleagues at the Uniformed Services University of the Health Sciences and Walter Reed Army Medical Center.

9 Mar 2010

Antibiotics program of Giant Eagle results in more than $3M in free prescriptions for customers

Pittsburgh-based food and fuel retailer Giant Eagle, Inc. launched its free antibiotics program in September of 2009, and is pleased to announce that the program has resulted in more than $3 million in free prescriptions for customers in the company's four-state operating area.

15 Feb 2010

Patients with rare autoimmune disease produce antibodies that disarm immune proteins

Two studies published online on February 1 in the Journal of Experimental Medicine (www.jem.org) reveal that patients with a rare autoimmune disease produce antibodies that attack microbe-fighting immune proteins called cytokines.

1 Feb 2010

Wrestlers are at higher risk for skin infections than other athletes

As high school and college wrestlers return to the mats in preparation for February tournaments and post-season championships, their risk for the skin infection Methicillin-Resistant Staphylococcus Aureus (MRSA) increases significantly.

30 Jan 2010

Genome study could help prevent devastating epidemics in the future

A team of collaborating scientists at The Methodist Hospital Research Institute in Houston, the Broad Institute in Boston, Mount Sinai Hospital in Toronto, and the Ontario Agency for Health Protection and Promotion (OAHPP) have sequenced almost 100 full genomes from three successive epidemics of flesh-eating bacteria.

27 Jan 2010

Galderma S.A. offers $3.75 million to NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a new class of anti-infectives for treating multi-drug resistant pathogens, announced today that it has received $3.75 million in milestone payments from partner Galderma S.A.

11 Jan 2010

LSUHSC receives $2.1 million grant for pneumonia research

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to further his work on a discovery that plays a critical role in the body's defense against pneumonia.

8 Jan 2010

Researchers develop new approach for treating and healing skin abscesses

Researchers at the Albert Einstein College of Medicine of Yeshiva University have developed a new approach for treating and healing skin abscesses caused by bacteria resistant to most antibiotics.

23 Dec 2009

New community-associated strain of MRSA more apt to cause serious problems

The often feared and sometimes deadly infections caused by MRSA - methicillin-resistant Staphylococcus aureus - are now moving out of hospitals and emerging as an even more virulent strain in community settings and on athletic teams, and raising new concerns about antibiotic resistance.

23 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

Cubist Pharmaceuticals signs definitive agreement to acquire Calixa Therapeutics

Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

14 Dec 2009

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

DermaGen AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" - announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin's weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease.

2 Dec 2009

Community-based program proves to be successful in reducing skin infections in Australian aboriginal children

A community-based program aimed at reducing the burden of skin disease across remote communities in Australia's Northern Territory has been successful according to a study published November 24 in the open-access journal PLoS Neglected Tropical Diseases.

25 Nov 2009

Scientists identify compounds that hold promise for treating parasitic infection

Using an unconventional approach that they designed, University of Pittsburgh drug discoverers and their collaborators at Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection that many consider one of the world's most overlooked diseases.

4 Nov 2009

Patients who acquire SSTIs in healthcare settings may stay longer in hospitals to control the infection

Patients who acquire skin and soft tissue infections (SSTIs) in a hospital or other healthcare setting may be more likely to receive inappropriate antibiotic therapy at the beginning of their treatment. As a result, they also may have significantly longer hospital stays to control the infection.

31 Oct 2009

Bacterial or viral skin infections continue to grow among high school and college athletes, survey reveals

A recent survey of nearly 650 athletic trainers across the U.S. revealed that in the past 12 months nearly 76 percent of the respondents' athletic programs, mostly high school- and college-based, bacterial or viral skin infections have developed.

30 Oct 2009

Keraderm raises $2.5 million from institutional investor

Keraderm Corp. announced the closing today of a $2.5 million dollar Series A investment by NewVa Capital Partners, LP. Currently starting clinical trials, the company's platform harnesses phototherapy technology to treat nail and skin infections. NewVa Capital Partners is a private equity and venture capital fund managed by Third Security, LLC and provides early stage investments in companies located or considering location in the NewVa region of southwest Virginia. This is Keraderm's first institutional investment round.

24 Oct 2009

Fero Industries to acquire Pyro Pharmaceuticals

Fero Industries, Inc. (the “Company”) is pleased to announce that the Company has entered into a Definitive Agreement to acquire Pyro Pharmaceuticals, Inc. of Irvine, California.

15 Oct 2009

Harvard researchers unite in fight against antibiotic resistance

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance."

14 Oct 2009